Resumen
The role of tumor necrosis factor-a (TNF-a) in Alzheimer?s disease (AD) has recently become a topic of debate. TNF-a levels increase in the blood of patients with AD, and amyloid beta (Aß) plaques contain TNF-a deposits. The therapeutic efficacy of blocking TNF-a in patients with AD remains controversial as it is mostly based on preclinical studies. Thus, whether and how TNF-a contributes to amyloidogenic processes in AD is still an open question to be addressed. We analyzed plasma TNF-a and Aß42 levels in patients with subjective cognitive impairment (SCI), mild cognitive impairment (MCI), and AD, and in healthy volunteers (HLT). In addition, we performed correlation analysis to evaluate whether changes in plasma TNF-a levels correlate with cognitive decline, Aß42 levels, age, and BMI, which are all factors considered to contribute to or predispose individuals to AD. We found that TNF-a and Aß42 plasma levels were higher in patients with AD than in HLT individuals. High TNF-a levels were also observed in patients with SCI, in whom TNF-a and Aß42 levels were negatively correlated. Notably, TNF-a did not affect the amyloidogenic pathway in human microglial cultures exposed to 48 h of incubation, although it did trigger neuroinflammatory processes. These results imply that high TNF-a levels are more likely to be a clinical condition linked to AD than are direct contributors. Nonetheless, elevated levels of TNF-a in early-stage patients, like those with SCI and MCI, may provide a distinguishing feature for identifying clinical profiles that are at risk of having a poorer outcome in AD and could benefit from tailored therapies.